Furthermore, the benefits of GLP-1 RA now extend to patients with peripheral artery disease (PAD) and T2DM
The rise of GLP-1 drugs critically rested on the coming together of a number of conceptual and experimental advances made by a variety of researchers with different skills around the world, both male and female
in patients with T2DM (38) found that continuous GLP-1 administration via a subcutaneous pump to raise serum GLP-1 levels from a mean of 9.7 pM at baseline to 282 pM over 6 weeks significantly reduced plasma glucose concentrations, improved glycated hemoglobin, and enhanced insulin sensitivity and -cell function compared to placebo, with no significant limiting side effects reported
DOI: 10.2337/db10-0474 Shaefer CF Jr et al (2015): User's guide to mechanism of action and clinical use of GLP-1 receptor agonists
Otherwise, we are contributing to the countrys health care affordability crisis, Hashmi said
When in doubt, replace it